HeartBeam Patent Expands Cardiac Monitoring Platform to Include Heart Failure and Structural Heart Disease Capabilities

HeartBeam Inc. (NASDAQ: BEAT) announced it has received a new U.S. patent that expands the capabilities of its credit card-sized, cable-free ECG device to include acoustic sensing and thoracic impedance measurement. This enhancement allows the device to function as a digital stethoscope and assess fluid accumulation in the chest, supporting future applications in structural heart disease and heart failure monitoring. Importantly, the new features are integrated without altering the existing form factor of the device, which is designed for patient-operated use outside medical facilities.

The patent strengthens HeartBeam's intellectual property portfolio, adding capabilities that could enable earlier detection of heart valve abnormalities and fluid congestion in heart failure patients. According to the company, this development advances its strategy of creating a multi-modal ambulatory cardiac sensing platform. The patent expands HeartBeam's global patent portfolio to 26 issued patents, covering signal acquisition, ECG synthesis algorithms, diagnostic applications, and device hardware. The company's technology is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG, providing actionable heart intelligence for physicians.

HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to technology enablement. The new patent is expected to support the development of a portable, patient-operated device that can monitor for heart failure and structural heart disease, potentially improving early detection and management of these conditions.

For more details, the full press release is available at https://ibn.fm/jgVf0. Information about the cleared indications for use can be found at https://www.heartbeam.com/indications. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.

This patent expansion underscores HeartBeam's commitment to transforming cardiac care by enabling comprehensive monitoring capabilities in a portable, patient-friendly device. By integrating acoustic sensing and thoracic impedance measurement, the company aims to address critical needs in heart failure and structural heart disease management, potentially reducing hospitalizations and improving patient outcomes.

The addition of these capabilities to HeartBeam's existing platform represents a significant step toward a multi-modal ambulatory sensing system that can provide continuous, actionable data to physicians. As the company continues to develop its technology, the new patent lays the groundwork for future applications that could expand the role of remote cardiac monitoring in managing chronic conditions.